Prilenia
is an Israel-based biotechnology company that develops and commercializes neuroprotective therapeutics for the treatment of neurodegenerative diseases... Read morePrilenia
is an Israel-based biotechnology company that develops and commercializes neuroprotective therapeutics for the treatment of neurodegenerative diseases... Read more
News
Feb 18, 2025
Clinical Trials Arena
Prilenia: Four regimens fail endpoints simultaneously in HEALEY ALS trial
Dec 25, 2024
Pharamceutical Technology
Prilenia: Pridopidine hydrochloride by Prilenia Therapeutics Development for Huntington Disease: Likelihood of Approval
Nov 05, 2024
FinanzNachrichten
Prilenia: Prilenia Therapeutics B.V.: Prilenia to Present Pridopidine Data at the Huntington Study Group (HSG) 2024 Congress
Sep 30, 2024
Pharmafile
Prilenia: Prilenia appoints new management staff to advance company's development and commercialisation plans
Sep 03, 2024
FinanzNachrichten
Prilenia: Prilenia Therapeutics B.V.: Prilenia's Pridopidine for Huntington's Disease Accepted for European Marketing Authorisation Review
Jul 15, 2024
Clinical Trials Arena
Prilenia: IROS, Prilenia and IHA team up for Huntington's disease trial
Apr 12, 2024
FinanzNachrichten
Prilenia: Prilenia Therapeutics B.V.: Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024
Mar 13, 2024
Pharmaceutical Business Review
Prilenia: Prilenia Therapeutics plans MAA submission to CHMP for pridopidine
Jan 19, 2024
FinanzNachrichten
Prilenia: Prilenia Therapeutics B.V.: Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS
Apr 26, 2023
Medthority
Prilenia: Phase III PROOF-HD clinical study of pridopidine reported on Huntington's disease
